鲍曼不动杆菌的耐药性及产ESBL和碳青霉烯酶分析

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (1): 30-33.

鲍曼不动杆菌的耐药性及产ESBL和碳青霉烯酶分析

李小宁¹, 李娟², 姚永红^1,3

¹皖南医学院弋矶山医院检验科,芜湖 241001,安徽
²临床药学部;
³安徽省歙县人民医院检验科,歙县 245200,安徽

收稿日期:2011-09-23 修回日期:2011-11-09 出版日期:2012-01-26 发布日期:2012-02-16
作者简介:李小宁,男,硕士,副教授,研究方向:细菌的耐药机制。E-mail: lixiaoning19702006@126.com

Analysis on resistance of Acinetobacter Baumannii and the extended spectrum beta-lactamases and carbapenemases

LI Xiao-ning¹, LI Juan², YAO Yong-hong^1,3

¹Department of Laboratory, Wannan Medical College Affiliated Yijishan Hospital, Wuhu 241001, Anhui, China;
²Department of Clinical Pharmacy
³Department of Laboratory, Shexian County People's Hospital, Shexian 245200, Anhui, China

Received:2011-09-23 Revised:2011-11-09 Online:2012-01-26 Published:2012-02-16

摘要/Abstract

摘要： 目的: 分析我院鲍曼不动杆菌的耐药性及产超广谱β-内酰胺酶(ESBL)和产碳青霉烯酶情况。方法: K-B法进行药物敏感试验, 运用表型确证试验检测ESBL, 改良Hodge试验检测碳青霉烯酶。结果: 135株鲍曼不动杆菌中,对亚胺培南和美罗培南的耐药率高达 72.6%,对阿米卡星、头孢噻肟等10种抗菌药物耐药率为 61.5%~100.0%,对头孢哌酮/舒巴坦的耐药率最低为 34.8%,其次是左氧氟沙星耐药率为 54.1%。其中有22株检出ESBL占 16.3%;46株检出碳青霉烯酶占 34.1%。结论: 我院鲍曼不动杆菌耐药率高,应加强细菌检测和药敏试验,指导临床合理应用抗菌药物。对于临床经验用药建议选用头孢哌酮/舒巴坦;鲍曼不动杆菌对β-内酰胺类药物耐药可能与产ESBL和碳青霉烯酶有关。

关键词: 鲍曼不动杆菌, 耐药性, ESBL, 碳青霉烯酶

Abstract: AIM: To analyze drug resistance of Acinetobacter Baumannii and detect the rate of extended spectrum beta-lactamases and carbapenemases which produced by Acinetobacter Baumannii in the hospital.METHODS: The disk diffusion method(K-B)for drug susceptibility testing was used, Clinical and Laboratory Standards Institute(CLSI) was taken for determing ESBL,the carbapenemases was modified by Hodge test.RESULTS: The susceptibility test to antibioties showed the resistance rates were 72.6% to Imipenem and Meropenem, 61.5%-100% to 10 antibioties including Amikacin and Cefotaxime, 34.8% to Cefoperazone/Sulbactam, 54.1% to Levofloxacin. In 135 strains, there were 22 produced ESBL(16.3%), 46 produced carbapenemases(34.1%).CONCLUSION: The drug resistance rate of Acinetobacter Baumannii is high in the hospital, it should be intensified in bacterium detection and drug susceptibility test to guide clinical drug usage more reasonability. Cefoperazone/Sulbactam will be advised as clinical experience of medication. The resistance to beta-lactam in Acinetobacter Baumannii is possibly related to ESBL and carbapenemases.

Key words: Acinetobacter Baumannii, Drug resistance, ESBL, Carbapenemases

中图分类号:

R978.1⁺1

李小宁, 李娟, 姚永红. 鲍曼不动杆菌的耐药性及产ESBL和碳青霉烯酶分析[J]. 中国临床药理学与治疗学, 2012, 17(1): 30-33.

LI Xiao-ning, LI Juan, YAO Yong-hong. Analysis on resistance of Acinetobacter Baumannii and the extended spectrum beta-lactamases and carbapenemases[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(1): 30-33.

[1]	王秀, 季麒麟, 裴文俊, 曾颖. 3-溴丙酮酸-胆固醇酯增强乳腺癌细胞对他莫昔芬敏感性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1093-1100.
[2]	袁星, 苏琰, 胥振国, 李自生. 临床分离鲍曼不动杆菌耐药表型和质粒介导喹诺酮类耐药基因研究[J]. 中国临床药理学与治疗学, 2021, 26(10): 1111-1117.
[3]	符佩姝，孙凤军，冯伟，熊丽蓉，李晓宇，夏培元. 多重耐药鲍曼不动杆菌感染的药物治疗进展[J]. 中国临床药理学与治疗学, 2019, 24(10): 1181-1187.
[4]	李楠，黄海涛，雍小兰. 1例误诊为中间葡萄球菌肺部感染的药学监护[J]. 中国临床药理学与治疗学, 2017, 22(9): 1067-1071.
[5]	蒋程，李芳琼，叶佐武，孙云峰，张美玲，李功华. 基于PLSR算法的CR-KP检出率与抗菌药物使用相关性研究[J]. 中国临床药理学与治疗学, 2017, 22(8): 904-909.
[6]	高家林，张魏，刘春声，朱玉，夏礼斌，陈月平，赵咏莉，何春玲，邢春燕，王勇，张斌华，陶秀彬. 皖南地区898例糖尿病足病及烧烫伤创面分泌物培养病原菌及耐药分析[J]. 中国临床药理学与治疗学, 2016, 21(7): 796-801.
[7]	范芳华，吴国友，周筱琼，肖震，程璐. siHybrids分子对耐药肺炎克雷伯菌kpc-2抑制作用研究[J]. 中国临床药理学与治疗学, 2016, 21(5): 490-494.
[8]	翁幸鐾，朱可奇，孙定河，史煜波，胡丽庆，王盛. 10种单味中药对鲍曼不动杆菌的抗菌作用和对主动外排机制抑制作用的研究[J]. 中国临床药理学与治疗学, 2016, 21(12): 1367-1371.
[9]	叶有娣，谢家政. 多重耐药鲍曼不动杆菌治疗药物研究进展[J]. 中国临床药理学与治疗学, 2016, 21(1): 116-120.
[10]	罗丹, 郝刚, 林思思, 郭文靖, 夏宇轩, 吕良忠. 替加环素临床耐药性的研究进展[J]. 中国临床药理学与治疗学, 2015, 20(4): 466-468.
[11]	李娟, 李小宁, 钟正灵, 储冀汝, 余文涛, 张雪峰, 谢海棠. 中药单体白花丹醌对鲍曼不动杆菌的耐药逆转作用[J]. 中国临床药理学与治疗学, 2015, 20(2): 155-159.
[12]	刘衍伶, 邓林强, 胡龙华, 杭亚平, 丁慧, 钟桥石, 胡晓彦, 王小中. 耐碳青霉烯类肺炎克雷伯菌耐药机制及呼吸机相关性感染的流行病学分析[J]. 中国临床药理学与治疗学, 2015, 20(10): 1137-1143.
[13]	汪红, 胡龙华, 宁长秀, 杭亚平, 钟桥石, 胡晓彦, 章白苓, 贾坤如. 耐碳青霉烯类抗生素鲍曼不动杆菌耐药机制的研究[J]. 中国临床药理学与治疗学, 2014, 19(10): 1093-1098.
[14]	何先弟, 颜培娥, 邹琪, 汪华学. 血必净对鲍曼不动杆菌脓毒症大鼠中性粒细胞翻译控制肿瘤蛋白表达的影响[J]. 中国临床药理学与治疗学, 2014, 19(1): 29-32.
[15]	谢刚, 安昌勇, 张才全, 唐华. 肠道抗生素行肠道准备后对大肠杆菌耐药的影响[J]. 中国临床药理学与治疗学, 2013, 18(4): 433-437.